468 related articles for article (PubMed ID: 23400280)
1. The France-PDT study: a national prospective observational cohort survey on the use of methyl-aminolevulinate photodynamic therapy in France, with up to 6-month follow-up.
Farhi D; Bedane C; Savary J; Basset-Seguin N
Eur J Dermatol; 2013; 23(1):68-76. PubMed ID: 23400280
[TBL] [Abstract][Full Text] [Related]
2. Methyl-aminolevulinate photodynamic therapy for the treatment of actinic keratoses and non-melanoma skin cancers: a retrospective analysis of response in 462 patients.
Fai D; Arpaia N; Romano I; Vestita M; Cassano N; Vena GA
G Ital Dermatol Venereol; 2009 Jun; 144(3):281-5. PubMed ID: 19528909
[TBL] [Abstract][Full Text] [Related]
3. Real-life practice study of the clinical outcome and cost-effectiveness of photodynamic therapy using methyl aminolevulinate (MAL-PDT) in the management of actinic keratosis and basal cell carcinoma.
Annemans L; Caekelbergh K; Roelandts R; Boonen H; Leys C; Nikkels AF; van Den Haute V; van Quickenborne L; Verhaeghe E; Leroy B
Eur J Dermatol; 2008; 18(5):539-46. PubMed ID: 18693157
[TBL] [Abstract][Full Text] [Related]
4. Methyl aminolevulinate-PDT for actinic keratoses and superficial nonmelanoma skin cancers.
Ortiz-Policarpio B; Lui H
Skin Therapy Lett; 2009; 14(6):1-3. PubMed ID: 19609473
[TBL] [Abstract][Full Text] [Related]
5. Risk of acute postoperative hypertension after topical photodynamic therapy for non-melanoma skin cancer.
Borroni RG; Carugno A; Rivetti N; Arbustini E; Brazzelli V
Photodermatol Photoimmunol Photomed; 2013 Apr; 29(2):73-7. PubMed ID: 23458390
[TBL] [Abstract][Full Text] [Related]
6. Fractionated aminolevulinic acid-photodynamic therapy provides additional evidence for the use of PDT for non-melanoma skin cancer.
de Haas ER; de Vijlder HC; Sterenborg HJ; Neumann HA; Robinson DJ
J Eur Acad Dermatol Venereol; 2008 Apr; 22(4):426-30. PubMed ID: 18031503
[TBL] [Abstract][Full Text] [Related]
7. Methyl aminolevulinate: actinic keratoses and Bowen's disease.
Morton CA
Dermatol Clin; 2007 Jan; 25(1):81-7. PubMed ID: 17126745
[TBL] [Abstract][Full Text] [Related]
8. European guidelines for topical photodynamic therapy part 1: treatment delivery and current indications - actinic keratoses, Bowen's disease, basal cell carcinoma.
Morton CA; Szeimies RM; Sidoroff A; Braathen LR
J Eur Acad Dermatol Venereol; 2013 May; 27(5):536-44. PubMed ID: 23181594
[TBL] [Abstract][Full Text] [Related]
9. [PDT panoramic view. Principle, photosensitizers, light sources and validated indications in dermatology].
Basset-Seguin N
Ann Dermatol Venereol; 2013 Nov; 140 Suppl 2():223-8. PubMed ID: 24199714
[TBL] [Abstract][Full Text] [Related]
10. The relationship between protoporphyrin IX photobleaching during real-time dermatological methyl-aminolevulinate photodynamic therapy (MAL-PDT) and subsequent clinical outcome.
Tyrrell JS; Campbell SM; Curnow A
Lasers Surg Med; 2010 Sep; 42(7):613-9. PubMed ID: 20806386
[TBL] [Abstract][Full Text] [Related]
11. Aminolevulinic acid and methyl aminolevulinate equally effective in topical photodynamic therapy for non-melanoma skin cancers.
Tarstedt M; Gillstedt M; Wennberg Larkö AM; Paoli J
J Eur Acad Dermatol Venereol; 2016 Mar; 30(3):420-3. PubMed ID: 26841041
[TBL] [Abstract][Full Text] [Related]
12. Methyl aminolaevulinate-photodynamic therapy for actinic keratoses, squamous cell carcinoma in situ and superficial basal cell carcinoma employing a square wave intense pulsed light device for photoactivation.
Downs AM; Bower CB; Oliver DA; Stone CA
Br J Dermatol; 2009 Jul; 161(1):189-90. PubMed ID: 19416229
[No Abstract] [Full Text] [Related]
13. Is the pain of topical photodynamic therapy with methyl aminolevulinate any different from that with 5-aminolaevulinic acid?
Ibbotson SH; Valentine R; Hearn R
Photodermatol Photoimmunol Photomed; 2012 Oct; 28(5):272-3. PubMed ID: 22971196
[TBL] [Abstract][Full Text] [Related]
14. Methyl aminolaevulinate-photodynamic therapy: a review of clinical trials in the treatment of actinic keratoses and nonmelanoma skin cancer.
Lehmann P
Br J Dermatol; 2007 May; 156(5):793-801. PubMed ID: 17419691
[TBL] [Abstract][Full Text] [Related]
15. Methyl aminolevulinate-based photodynamic therapy of Bowen´s disease: Observational study of 21 lesions.
Gómez C; Cobos M; Alberdi E
Photodiagnosis Photodyn Ther; 2019 Jun; 26():295-299. PubMed ID: 30986539
[TBL] [Abstract][Full Text] [Related]
16. European guidelines for topical PDT part 1 JEADV 2013; 27: 536-544.
Skaria AM
J Eur Acad Dermatol Venereol; 2014 May; 28(5):673. PubMed ID: 23981061
[No Abstract] [Full Text] [Related]
17. A cost analysis of photodynamic therapy with methyl aminolevulinate and imiquimod compared with conventional surgery for the treatment of superficial basal cell carcinoma and Bowen's disease of the lower extremities.
Aguilar M; de Troya M; Martin L; Benítez N; González M
J Eur Acad Dermatol Venereol; 2010 Dec; 24(12):1431-6. PubMed ID: 20456549
[TBL] [Abstract][Full Text] [Related]
18. Methylaminolaevulinate-based photodynamic therapy of Bowen's disease and squamous cell carcinoma.
Calzavara-Pinton PG; Venturini M; Sala R; Capezzera R; Parrinello G; Specchia C; Zane C
Br J Dermatol; 2008 Jul; 159(1):137-44. PubMed ID: 18489606
[TBL] [Abstract][Full Text] [Related]
19. Photodynamic therapy in the treatment of extensive Bowen's disease.
López N; Meyer-Gonzalez T; Herrera-Acosta E; Bosch R; Castillo R; Herrera E
J Dermatolog Treat; 2012 Dec; 23(6):428-30. PubMed ID: 21787214
[TBL] [Abstract][Full Text] [Related]
20. Photodynamic therapy of non-melanoma skin cancer with methyl aminolaevulinate is associated with less pain than with aminolaevulinic acid.
Gaál M; Otrosinka S; Baltás E; Ocsai H; Oláh J; Kemény L; Gyulai R
Acta Derm Venereol; 2012 Mar; 92(2):173-5. PubMed ID: 22113788
[No Abstract] [Full Text] [Related]
[Next] [New Search]